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Abstract: Chagas’ disease, caused by the protozoan parasite Trypanosoma cruzi, affects 8-10 
million people across the Latin American population and is responsible for around 12,500 
deaths per annum. The current frontline treatments, benznidazole and nifurtimox, are 
associated with side effects and lack efficacy in the chronic stage of the disease, leading to 
an urgent need for new treatments. A high throughput screening campaign against the 
physiologically relevant intracellular form of the parasite identified a series of 2,4-diamino-
6-methylpyrimidines. Demonstrating the series did not work through the anti-target 
TcCYP51, and was generally cytocidal, confirmed its suitability for further development. This 
study reports the optimisation of selectivity and metabolic stability of the series and 
identification a suitable lead for further optimisation. 
  
  
Chagas’ Disease
1
, an infection caused by the parasite Trypanosoma cruzi, is endemic in 21 
countries across Latin America and is estimated to be responsible for around 12,500 deaths 
per Annum
2
. The disease is also found in many other parts of the world, mainly due to 
migration. Chagas’ disease is characterized by an initial acute phase, which is fatal for 
around 5% of children. This is followed by a long-term chronic phase, which can eventually 
be fatal due to associated cardiac problems3,4. The standard treatment is based on 
benznidazole and nifurtimox, nitro-aromatic drugs that effectively clear parasites in the 
acute phase, but are less effective in the chronic phase5. There are no current alternatives to 
benznidazole or nifurtimox and recent clinical trials of posaconazole, an inhibitor of the 
enzyme T. cruzi C14 α-demethylase (commonly known as TcCYP51) did not give promising 
results
6
. Thus, there is an urgent need for novel chemical classes that target T. cruzi through 
alternative mechanisms to TcCYP51. 
To this end, we have developed a screening cascade to identify chemical series with the 
potential to treat Chagas’ disease (see fig. 1)7. An initial high throughput phenotypic screen 
against the intracellular amastigote form of T. cruzi identified compounds that inhibit 
parasite growth with selectivity over host Vero cells7. These compounds were then counter-
screened against TcCYP51 to identify those acting via alternative, non-TcCYP51 
mechanisms8. Alongside this, a second T. cruzi assay identified compounds acting through a 
cytocidal, rather than cytostatic mode of action
7
. Series thus identified could be further 
optimized to give compounds suitable for progression into an in vivo efficacy model of 
Chagas’ disease. 
 
  
Figure 1: Screening cascade to identify chemical series for development against T. cruzi 
A set of >13,000 compounds with antimalarial activity was released by GSK (referred to as 
TCAMS)
9
, and this set was screened through the cascade described. One of the series 
identified from this screen was exemplified by compound 1 (Table 1), which demonstrated a 
pEC50 against T. cruzi parasites of 6.9 and a 40-fold selectivity window versus host Vero cells. 
Compound 1 was further profiled through the highlighted cascade, showing cytocidal 
behavior and no TcCYP51 activity (i.e. pEC50 <5). In terms of in vitro DMPK properties, the 
compound had low kinetic solubility but was stable in mouse liver microsomes (MLM). 
Further examination of the hit set identified a number of close analogues that all contained 
the 1,4-dianilino moiety, with either amide or sulfonamide linkers, which further validated 
this series. These analogues all had a relatively similar selectivity window versus the host 
cells (40-60 fold) and poor solubility (data not shown). This programme therefore focused 
on optimizing potency, selectivity and solubility to identify compounds suitable for 
progression into an in vivo model of Chagas’ disease.  
Table 1. Hit Compound 1.  
 
No. Tc pEC50 
a
 Vero 
pEC50
a
 
Selectivity 
b
 Solubility 
µM c 
Clint (MLM) 
ml/min/g 
d 
 
TcCYP51 
pIC50 
Cytocidal 
1 6.8±0.2 5.2±0.3 40 20 0.7 <5 Yes 
a 
Tc refers to activity in T. cruzi amastigote cultures in Vero cells.  pEC50 value shown as mean 
values from three EC50 determinations ± standard deviation. 
b Selectivity refers to Vero 
pEC50/Tc pEC50. 
c Kinetic solubility measured in water from a DMSO solution of compound. d 
Clint (MLM) refers to intrinsic clearance measured in mouse liver microsomes 
  
  
 
This 2,4-diamino-6-methylpyrimidine motif has previously been reported to show 
antimalarial activity10 and has more recently been identified in screens against the 
kinetoplastids
11
. As far as we are aware, this is the first report of developing this compound 
series for the treatment of Chagas’ disease. 
Chemistry to access the desired analogues is described in Schemes 1-3.  Compounds with 
variations in the 2-pyrimidinyl position were synthesized according to Scheme 1
10
. 
Commercially available 2,4-dichloro-6-methylpyrimidine 2 was treated with dimethylamine, 
followed by a suitably substituted aniline to give compounds 4a-d, whilst treatment with m- 
or p-aminobenzoate, followed by hydrolysis of the ester, gave acids that were treated with 
TBTU and a relevant amine to give amides 5a-c. Compound 3 could also be reacted with 
alkyl amines under basic conditions to give compounds 6a-e, whilst treatment with 1,4-
trans-cyclohexanediamine and subsequent acylation gave 8a-b. Compounds 18a-e could be 
synthesized following an identical route, starting from suitably functionalized 2,4-
dichloropyrimidines. 
 
Scheme 1. Synthesis of 4a-d, 5a-c, 6a-e and 8a-b. (a) Me2NH, THF, 68%; (b) Aniline, 
Pd(
t
Bu3P)2, NaO
t
Bu, 1,4-dioxane, 120
o
C, 21-68%; (c) 1M NaOH, THF then TBTU, DIPEA, DMF; 
(d) 1,4-dioxane, 160
o
C; (e) R4-COCl, DIPEA, DCM. 
 
Analogues with variations to the pyrimidinyl 4-position were synthesised according to 
Scheme 2. The thiopyrimidine 9 was alkylated with iodomethane and the resulting thioether 
  
displaced by 3-methoxy-4-fluoro aniline to give 11. This was treated with POCl3 and the 
resulting chloro-group displaced by relevant amines to give compounds 13a-g. 
 
 
Scheme 2. Synthesis of 13a-g. (a) Iodomethane, potassium carbonate, DMSO, 48%; (b) 
Aniline, butan-1-ol, 110
o
C, 49%; (c) POCl3, 120
o
C, 59%; (d) R1R2-NH2, DIPEA, 1,4-dioxane, 
110
o
C 
In order to access 2-benzylamino-4-anilino compounds, 2,4-dichloro-6-methyl pyrimidine 14 
was treated with benzylamine, giving a mixture of the 2- and 4- substituted intermediates 
(15 and 16), which were easily separated and identified by NMR (Scheme 3). Compound 16 
was treated with 3-methoxy-4-fluoroaniline under acidic conditions to give 17a-c. 
 
Scheme 3. Synthesis of 17a-c. (a) Benzylamine, DIPEA, THF (b) relevant aniline, conc. HCl, 
EtOH, 50%. 
The focus of the initial medicinal chemistry program was to improve solubility and 
selectivity, targeting a pEC50 > 7 and cellular selectivity of > 100-fold in the intracellular 
amastigote assay7, solubility of > 250 µM and Clint < 5 ml/min/g. These parameters were 
based on previous experience of progressing compound series into in vivo models of Chagas’ 
disease12. Since this series was identified through a phenotypic screen, the molecular target 
  
was unknown; therefore we undertook a systematic exploration of the pyrimidine 
substituents to address the progression parameters. 
 
An initial strategy was to remove / replace the 1,4-dianilino moiety, which we believed 
could be a key driver of the poor solubility of 1, as well as presenting potential genotoxicity 
risks as the compound series progressed. Also, removal of the benzamide would reduce the 
number of aromatic rings, which could also help to improve solubility. The initial round of 
synthesis investigated whether either aminobenzamides or other substituted anilines would 
result in improved profiles (Table 2). The para-substituted piperidine amide 5a showed no 
toxicity against the host cells at the top concentration tested (50 µM), but had reduced 
potency compared to compound 1. Phenyl and benzyl amides, as exemplified by 5b and 5c, 
had a similar potency but reduced selectivity compared to 5a. Further exploration of the 
benzamides, including meta-substituted benzamides, failed to improve potency.  
 
Table 2: In vitro profile of analogues 5a-c, 4a-d and 6a-c.  
 
 
No. R Tc pEC50 
a
 Vero pEC50 
a
 Selectivity 
b
 Solubility µM c Clint (MLM) 
ml/min/g 
d
 
1 
 
6.8±0.2 5.2±0.3 40 20 0.7 
5a 
 
5.7±0.3 <4.3 >25 N/A N/A 
5b 
 
6.1±0.2 6.2±0.4 1.3 N/A N/A 
5c 
 
5.9±0.4 5.3±0.3 4 N/A N/A 
4a  5.8±0.3 <4.3 
>32 >250 10 
4b 
 
6.1±0 <4.3 >63 >250 15 
  
4c  5.9±0.3 <4.3 
>40 >250 14 
4d 
 
6.4±0.1 4.5±0.1 80 >250 17 
6a  5.5±0.3 <4.3 >16 >250 28 
6b 
 
5.9±0.1 <4.3 >40 >250 11 
6c  6.0±0.3 4.6±0.2 
25 >250 12 
a 
Tc refers to activity in T. cruzi amastigotes cultures in Vero cells. pEC50 values are shown as 
mean values from two EC50 determinations ± range (except 1, 4b where value is ± standard 
deviation from >2 determinations). b Selectivity refers to Vero pEC50/Tc pEC50. 
c Kinetic 
solubility measured in water from a DMSO solution of compound. d Clint (MLM) refers to 
intrinsic clearance measured in mouse liver microsomes. N/A means value was not 
measured 
 
Because the strategy of replacing the anilide with a benzamide had not led to improved 
compounds, we investigated a wider range of substituted anilines (exemplified by 4a-d in 
Table 2). Pleasingly, both m- and p-methoxy analogues (4a and 4b) showed similar potencies 
to compounds 5a-c with an improved selectivity window and solubility compared to 1. 
Alongside potency, microsomal clearance for 4a and 4b required further optimization; 
hence we synthesized further substituted anilines and benzylamines to address these issues. 
All attempts, as exemplified by 4c, 4d, and 6a-c led to analogues with similar potency and 
clearance values. 
 
As we had made a significant change to the original hit scaffold, we confirmed that 
compounds 4d and 6a did not inhibit TcCYP51 and both were cytocidal. Alongside that, 
profiling of 4d in a panel of potential off target receptors associated with in vivo toxicity, 
revealed that inhibition of hERG (pIC50 5.3) was a potential issue, due to its association with  
potentially fatal arrhythmia. This data did not stop the progression of the series, but would 
need addressing if the compound series were ultimately to be developed. 
. 
  
  
 
Encouraged by 4d and 6a, which were highly selective and soluble, further SAR was explored 
around these scaffolds to improve metabolic stability (See Tables 3 and 4) by removing the 
potential for N-demethylation of the 4-dimethylamino group. Analogues of 4d, represented 
by 13a-g (Table 3), where the dimethylamine was replaced with other alkyl amines, failed to 
significantly improve metabolic stability (where Clint
 
<5ml/min/g was targeted). Additionally, 
none of the changes, which introduced both polar and non-polar groups, led to a significant 
improvement in potency. 
 
Table 3: In vitro profile of analogues 13a-g.  
 
 
No. R Tc pEC50 
a
 Vero pEC50 
a
 Selectivity 
b
 Solubility 
µM c 
Clint
 
(MLM) d 
ml/min/g 
4d  6.4±0.3 4.5±0.1 80 >250 17 
13a 
 
6.0±0.4 4.8±0.2 16 160 17 
13b 
 
6.5±0.5 4.7±0.2 63 220 14 
13c 
 
5.1±0.4 <4.3 >6 >250 18 
13d 
 
5.8±0.3 4.6±0.2 16 >250 35 
13e 
 
5.1±0.2 4.4±0.1 5 219 N/A 
13f 
 
5.1±0.2 4.5±0.2 4 >250 35 
13g 
 
6.1±0.5 5.3±0.2 6.3 >250 8 
 
  
a 
Tc refers to activity in T. cruzi amastigote cultures in Vero cells.  pEC50 value shown as mean 
values from three EC50 determinations ± standard deviation. 
b
 Selectivity refers to Vero 
pEC50/Tc pEC50. 
c Kinetic solubility measured in water from a DMSO solution of compound. d 
Clint (MLM) refers to intrinsic clearance measured in mouse liver microsomes 
 
To further explore replacement of the 4-dimethylamino group, we focused on the 
introduction of substituted anilines. Due to concern that addition of a further aromatic ring 
could reduce solubility, these changes were introduced onto the benzyl substituted scaffold 
of 6a, rather than the aniline 4d, where the increased sp3 character might alleviate this 
potential issue
13
. As shown in Table 4, these analogues (17a-c) demonstrated improved 
potency whilst maintaining selectivity and solubility compared to compound 6a, although 
none of them improved the metabolic stability. 17c did show a significant improvement in 
potency compared to 6a, achieving our target of pEC50 > 7.0, and also contained significant 
structural changes. Because of this, 17c was further profiled in our cytostatic / cytocidal 
assay where it demonstrated cytostatic behavior, suggestive of a change in the mode of 
action of this compound. This was undesirable, because our previous experience of a 
cytostatic compound was that it would not achieve cures in in vivo models12. As such, this 
sub-series was not progressed further. 
 
Table 4: In vitro profile of analogues 17a-c.  
N
N
R
N
H  
 
No. R Tc pEC50 
a 
Vero 
pEC50 
a 
Selectivity 
b
 Solubility 
µM c 
Clint
 
(MLM) 
ml/min/g 
d
 
6a  5.5±0.3 <4.3 >16 >250 28  
17a 
 
6.4±0.4 5.1 20 >250 10  
17b 
 
6.7±0.1 5.1±0.1 40 >250 20  
  
17c 
 
7.1±0.4 5.3±0.1 63 180 10  
a 
Tc refers to activity in T. cruzi amastigotes cultures in Vero cells. pEC50 values are shown as 
mean values from three or more EC50 determinations ± standard deviation. 
b Selectivity 
refers to Vero pEC50/Tc pEC50. 
c 
Kinetic solubility measured in water from a DMSO solution of 
compound. 
d 
Clint (MLM) refers to intrinsic clearance measured in mouse liver microsomes 
 
Returning to the 2-(3-methoxy-4-fluoroanilino)-4-dimethylamino template of 4d, which 
retained the same in vitro profile as compound 1, we investigated variations to the 6-methyl 
group (Table 5), focusing on changes which could enhance metabolic stability. As can be 
seen from Table 5, all analogues investigated demonstrated a significant reduction in 
potency although 18e was the first compound in the series to demonstrate progressable 
metabolic stability. 
 
Table 5: In vitro profile of analogues 18a-e.  
 
 
No. R Tc pEC50 
a
 Vero pEC50 
a
 Selectivity 
b
 Solubility 
µM c 
Clint
 
(MLM) 
ml/min/g d 
4d  6.4±0.3 4.5±0.1 80 >250 17 
18a  5.4±0.1 <4.3 >13 160 29 
18b  5.1±0.1 <4.3 >6 >250 35 
18c  5.7±0.3 <4.3 >25 170 50 
18d  4.6±0.5 <4.3 >2 110 N/A 
18e N
O  
4.5±0.2 <4.3 
>1.6 
>250 3.4 
a 
Tc refers to activity in T. cruzi amastigotes cultures in Vero cells. pEC50 values are shown as 
mean values from three or more EC50 determinations ± standard deviation. 
b Selectivity 
refers to Vero pEC50/Tc pEC50. 
c 
Kinetic solubility measured in water from a DMSO solution of 
compound. 
d 
Clint (MLM) refers to intrinsic clearance measured in mouse liver microsomes. 
N/A means value was not measured 
  
 
As variations to the 4- and 6-positions of the pyrimidine had failed to identify compounds 
with suitable profiles to progress to in vivo studies, our focus returned to the pyrimidinyl 2-
position. From previous SAR (outlined within Table 1 and 2) it was known that variations in 
this position could be tolerated without loss of potency. Also, 18e gave us optimism that 
analogues with improved metabolic stability could be identified within the series. 
Table 6 shows a comparison of these analogues with 4d and 6a, where we were able to 
identify compounds with a similar level of potency, solubility and selectivity. Critically we 
observed a significant improvement in metabolic stability, most notably for compound 8b.  
This compound had a pEC50 of 6.4 as well as very good selectivity (100-fold) and solubility, 
and no activity versus TcCYP51. Compound 8b was also cytocidal, albeit with a narrow 
selectivity window; this lower selectivity likely being due to the two assays being run in 
different cell lines. Finally 8b was profiled against the same panel of off target receptors that 
was used for 4d, unfortunately showing no improvement.  In fact, further risks were 
identified; hERG (pIC50 5.4), Aurora B (pIC50 7.4, highlighting potential promiscuity issues 
with other kinases) and CB1 (pIC50 7.2, concerns of psychotropic effects). These changes 
demonstrated that the cyclohexyldiamine linker gave a scaffold with the potential for 
further modifications to improve the profile against T. cruzi, but introduced potential 
toxicity risks which could hamper the development of this series. 
Table 6: In vitro profile of analogues 4d, 6a, 6d-e and 8a-b.  
 
 
No. 
R 
Tc pEC50
a
 Vero 
pEC50 
a 
Selectivity 
b
 Solubility 
µM c 
Clint
 
(MLM) 
ml/min/g d 
4d 
 
6.4±0.3 4.5±0.1 80 >250 17 
6a  5.5± 0.3 <4.3 >16 >250 28 
6d  4.8±0.1 <4.3 >3 >250 3.8 
  
6e 
 
5.5±0.1 <4.3 
>16 
N/A N/A 
8a 
 
5.9±0.2 <4.3 
>40 
>250 N/A 
8b 
 
6.4±0.4 4.4±0.1 100 >250 4.2 
a 
Tc refers to activity in T. cruzi amastigotes cultures in Vero cells. pEC50 values are shown as 
mean values from three or more EC50 determinations ± standard deviation. 
b
 Selectivity 
refers to Vero pEC50/Tc pEC50. 
c Kinetic solubility measured in water from a DMSO solution of 
compound. 
d 
Clint (MLM) refers to intrinsic clearance measured in mouse liver microsomes. 
N/A means value was not measured 
 
In summary, a novel series of T. cruzi inhibitors was identified through high throughput 
screening against the intracellular parasite that were demonstrated to be cytocidal, and also 
to be working via a non-TcCYP51 mechanism. These initial hits suffered from poor selectivity 
and low solubility and microsomal stability. A series of compounds was therefore 
synthesized to address these concerns. The initial rounds of optimisation produced 
compound 17c, with acceptable potency and improved solubility and selectivity. However, 
17c was no longer cytocidal, suggesting that its mode of action had changed, and also 
highlighting the need to use TcCYP51 and cytocidality assays when working on a series 
where the mode of action was unknown. A different approach of using non-aromatic linkers 
to mimic the dianilino moiety of the initial hits led to 8b; this compound was moderately 
potent (pEC50 6.4), highly selective over the host Vero cells and displayed improved 
microsomal stability, albeit with increased off-target risks leading to the potential for in vivo 
toxicity. As the series was progressed phenotypically, it could potentially show 
polypharmacology, with different molecules having varying inhibition profiles, making 
optimisation challenging. Although further exploration of the scaffold could give compounds 
with suitable profiles for progression to in vivo studies, knowledge of the molecular targets 
and binding mode(s) of the series would facilitate this optimisation against targets which are 
cytocidal, and also offer strategies to design out off-target effects.  
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